Stefan Clemens Selected Research

Restless Legs Syndrome (Restless Legs)

2/2019	Adenosine A1-Dopamine D1 Receptor Heteromers Control the Excitability of the Spinal Motoneuron.
1/2018	Differential Dopamine D1 and D3 Receptor Modulation and Expression in the Spinal Cord of Two Mouse Models of Restless Legs Syndrome.
12/2017	Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1 receptor.
1/2017	Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome.
1/2017	Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.
1/2011	Effects of acute dopamine-agonist treatment in restless legs syndrome on heart rate variability during sleep.
1/2011	Possible sites of therapeutic action in restless legs syndrome: focus on dopamine and α2δ ligands.
7/2006	Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefan Clemens Research Topics

Disease

8	Restless Legs Syndrome (Restless Legs) 02/2019 - 07/2006
5	Pain (Aches) 01/2022 - 12/2012
3	Fibrosis (Cirrhosis) 01/2021 - 01/2013
2	Spinal Cord Injuries (Spinal Cord Injury) 01/2022 - 02/2019
2	Neuralgia (Stump Neuralgia) 01/2022 - 01/2020
1	Contusions 01/2022
1	Chronic Pain 01/2020
1	Heart Failure 01/2020
1	Hypertrophy 01/2020
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2020
1	Meningioma (Meningiomas) 01/2018
1	Neoplasms (Cancer) 01/2018
1	Hypertension (High Blood Pressure) 01/2013
1	Iron Deficiencies 01/2011
1	Sleep Wake Disorders 12/2004

Drug/Important Bio-Agent (IBA)

8	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 12/2004
5	Morphine (MS Contin)FDA LinkGeneric 01/2022 - 01/2017
4	Pramipexole (Mirapex)FDA LinkGeneric 01/2020 - 01/2011
3	Dopamine Receptors (Dopamine Receptor)IBA 01/2021 - 01/2017
3	Dopamine D3 ReceptorsIBA 01/2020 - 01/2013
3	Dopamine Agonists (Dopamine Agonist)IBA 01/2018 - 01/2011
2	Opioid Analgesics (Opioids)IBA 01/2022 - 01/2020
2	Levodopa (L Dopa)FDA LinkGeneric 01/2018 - 01/2017
1	Analgesics (Analgesic Drugs)IBA 01/2022
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021
1	CollagenIBA 01/2020
1	ecopipamIBA 01/2020
1	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 01/2020
1	Caffeine (No Doz)FDA LinkGeneric 02/2019
1	rotigotine FDA Link 12/2017
1	Adenosine (Adenocard)FDA LinkGeneric 01/2017
1	PlasticsIBA 01/2017
1	Opioid Receptors (Opioid Receptor)IBA 01/2014
1	Collagen Type I (Type I Collagen)IBA 01/2013
1	LigandsIBA 01/2011

Therapy/Procedure

2	Pain Management 01/2020 - 01/2020
2	Therapeutics 01/2020 - 02/2019
1	Analgesia 01/2020
1	Craniotomy 01/2018
1	Self-Help Devices (Assistive Technology) 01/2018
1	Endoscopes 01/2018
1	Aftercare (After-Treatment) 01/2011